Index Reshuffle: Divi's Laboratories Replaces Wipro in Sensex 50
What happened
A notice dated November 20 announced changes across several prominent indices. Divi's Laboratories entered the BSE Sensex 50, replacing Wipro. Laurus Labs was added to the BSE 100, replacing Punjab National Bank among other stocks. Additionally, Sagility was added to the BSE Focused IT index, replacing L&T Technology Services.
From indiatimes.com
Why it matters
These index changes affect the market valuation and passive investment flows of the companies involved. The inclusion of Divi's Laboratories in the Sensex 50 is noted to attract significant passive institutional investment. Similarly, Laurus Labs' inclusion in the BSE 100 is expected to boost visibility and attract passive institutional investment.
From indiatimes.com
Who's involved
- Divi's LaboratoriesEntered the BSE Sensex 50, replacing Wipro.
- WiproWas replaced by Divi's Laboratories in the Sensex 50.
- Laurus LabsWas added to the BSE 100.
- L&T Technology ServicesWas replaced by Sagility in the BSE Focused IT index.
- Punjab National BankWas replaced in the BSE 100.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Divi's LaboratoriesSpeculative
Could attract significant passive institutional investment and boost valuation due to Sensex 50 inclusion.
- Laurus LabsSpeculative
May attract passive institutional investment and boost visibility following BSE 100 inclusion.
- L&T Technology ServicesSpeculative
Could see reduced visibility and passive investment flows in its segment due to index exclusion.
- Punjab National BankSpeculative
May face reduced visibility and institutional capital allocation following index exclusion.
Keep exploring
The entities involved
-
Divi's Laboratories
Indian pharmaceutical stock company
Nothing else this week.
-
Wipro
Indian information technology services corporation headquartered in Bengaluru, India
Nothing else this week.
-
Laurus Labs
Indian pharmaceutical company
Nothing else this week.